MedTrace Logo

AI-Assisted Microbiome Analysis for Evaluating the Efficacy of MPRO3 and Gut Environmental Changes in Colon Cancer Surgery Patients

NCT07792980 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-08-28

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the effects of MPRO3(probiotics mixture) supplementation on surgical outcomes and gut health in patients undergoing surgery for colon cancer.The main question is whether MPRO3 supplementation before and after surgery can reduce postoperative infectious complications compared with placebo.Participants will take either MPRO3 or a placebo once daily for 13 weeks, from 1 week before surgery to 12 weeks after surgery. Researchers will compare the two groups to assess postoperative infectious complications, other clinical outcomes, and changes in the gut microbiome.

Conditions

  • Colon Neoplasms

Interventions

DIETARY_SUPPLEMENT

Placebo

Participants will receive one placebo capsule orally once daily after breakfast for 13 weeks.

DIETARY_SUPPLEMENT

MPRO3

Participants will receive one MPRO3 capsule orally once daily after breakfast for 13 weeks.

Sponsors & Collaborators

  • Nutriworks

    collaborator INDUSTRY

  • ImmunoBiome

    collaborator UNKNOWN

  • hy Co., LTD.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-04
Primary Completion
2028-04-12
Completion
2028-04-12

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07792980 on ClinicalTrials.gov